| Literature DB >> 25672296 |
Carla Andréa Avelar Pires1, Mario Fernando Ribeiro de Miranda1, Maraya de Jesus Semblano Bittencourt1, Arival Cardoso de Brito1, Marília Brasil Xavier1.
Abstract
BACKGROUND: Leprosy and HIV are diseases that have a major impact on public health in Brazil. Patients coinfected with both diseases, appear to be at higher risk to develop leprosy reactions.Entities:
Mesh:
Year: 2015 PMID: 25672296 PMCID: PMC4323695 DOI: 10.1590/abd1806-4841.20153048
Source DB: PubMed Journal: An Bras Dermatol ISSN: 0365-0596 Impact factor: 1.896
Distribution of patients according to gender, age, operational and clinical classification*
| General characteristics | Evaluated groups | p-value | ||||
|---|---|---|---|---|---|---|
| Group I (HIV-leprosy) | Group II (leprosy) | |||||
| N | % | N | % | |||
|
| ||||||
| Male | 27 | 67.5 | 72 | 67.3 | Chi-square | |
| Female | 13 | 32.5 | 35 | 32.7 | p = 0.8623 | |
| Total | 40 | 100 | 107 | 100 | ||
|
| ||||||
| ≤ 15 | 1 | 2.5 | 12 | 11.2 | G test | |
| 16 to 30 | 10 | 25.0 | 31 | 29.0 | p = 0.0872 | |
| 31 to 59 | 28 | 70.0 | 55 | 51.4 | ||
| ≥ 60 | 1 | 2.5 | 9 | 8.4 | ||
| Total | 40 | 100 | 107 | 100 | ||
|
| ||||||
| Mean ± Standard deviation | 37.8±10.4 | 36.2±16.5 | T test | |||
| p = 0.4897 | ||||||
|
| ||||||
| Paucibacillary | 28 | 70 | 21 | 19.6 | Relative risk = 3.0 | |
| Multibacillary | 12 | 30 | 86 | 80.4 | p < 0.0001 | |
| Total | 40 | 100 | 107 | 100 | 95%CI = 2.0 - 4.6 | |
|
| ||||||
| Pure neural | 0 | 0.0 | 3 | 2.8 | G test | |
| Indeterminate | 3 | 7.5 | 4 | 3.7 | p < 0.0001 | |
| TT | 7 | 17.5 | 14 | 13.1 | ||
| BT | 18 | 45.0 | 11 | 10.3 | ||
| BB | 10 | 25.0 | 43 | 40.2 | ||
| BL | 2 | 5.0 | 21 | 19.6 | ||
| LL | 0 | 0.0 | 11 | 10.3 | ||
| Total | 40 | 100 | 107 | 100 | ||
Distribution of patients according to the clinical characteristics of leprosy reactions
| Clinical characteristics in patients with ENL | Evaluated groups | Statistical tests | ||||
|---|---|---|---|---|---|---|
| Group I (HIV-leprosy) | Group II (leprosy) | |||||
| N | % | N | % | |||
|
| ||||||
| Yes | 15 | 37.5 | 60 | 56.1 | Relative risk = 0.47 | |
| No | 25 | 62.5 | 47 | 43.9 | p = 0.0026 | |
| Total | 40 | 100 | 107 | 100 | 95%CI = 0.28-0.79 | |
|
| ||||||
| Type I | 13 | 86.7 | 34 | 56.6 | G Test | |
| Type II | 2 | 13.3 | 22 | 36.7 | p = 0.0750 | |
| Type I e II | 0 | 0 | 4 | 6.7 | ||
| Total | 15 | 100 | 60 | 100 | ||
|
| ||||||
| Present | 7 | 17.5 | 27 | 25.2 | Chi-square | |
| Absent | 33 | 82.5 | 80 | 74.8 | p = 0.4414 | |
| Total | 40 | 100 | 107 | 100 | ||
FIGURE 1A. Lesion in a patient coinfected with HIV/leprosy, Borderline-Tuberculoid (BT) form, in reversal reaction (RR). B. Lesions in regression after 30 days of treatment with prednisone
FIGURE 2Fragmented granuloma in patients with HIV/leprosy coinfection. Photomicrography in HE with 40x augmentation
Distribution of patients with reversal reaction according to histopathological characteristics
| Histopathological characteristics in patients with RR | Evaluated groups | Statistical tests | ||||
|---|---|---|---|---|---|---|
| Group I | GroupII | |||||
| (HIV-leprosy) | (Leprosy) | |||||
|
| ||||||
| Yes | 13 | 100.0 | 33 | 100.0 | - | |
| No | 0 | 0.0 | 0 | 0.0 | ||
| Total | 13 | 100.0 | 33 | 100.0 | ||
|
| ||||||
| 1+ | 0 | 0.0 | 14 | 42.4 | Exact Fisher | |
| 2+ | 13 | 100.0 | 19 | 57.6 | p = 0.0042 | |
| Total | 13 | 100.0 | 33 | 100.0 | ||
|
| ||||||
| ≤10% | 0 | 0.0 | 2 | 6.3 | G Test | |
| 11 to 50% | 13 | 100.0 | 7 | 21.9 | p < 0.0001 | |
| > 50% | 0 | 0.0 | 23 | 71.9 | ||
| Total | 13 | 100.0 | 32 | 100.0 | ||
|
| ||||||
| Yes | 13 | 100.0 | 15 | 45.5 | Exact Fisher | |
| No | 0 | 0.0 | 18 | 54.5 | p = 0.0005 | |
| Total | 13 | 100.0 | 33 | 100.0 | ||
|
| ||||||
| 1+ | 0 | 0.0 | 14 | 93.3 | Exact Fisher | |
| 2+ | 13 | 100.0 | 1 | 6.7 | p < 0.0001 | |
| Total | 10 | 100.0 | 15 | 100.0 | ||
FIGURE 3Giant cells with increase in size and number, in a patient coinfected with HIV/leprosy. Photomicrography in HE with 40x augmentation
Distribution of patients with ENL according to histopathological characteristics
| Histopathological characteristics in patients with ENL | Evaluated groups | Statistical tests | ||||
|---|---|---|---|---|---|---|
| Group I | Group II | |||||
| (HIV-leprosy) | (Leprosy) | |||||
| N | % | N | % | |||
|
| ||||||
| Yes | 2 | 100.0 | 9 | 56.3 | Exact Fisher | |
| No | 0 | 0.0 | 7 | 43.8 | p = 0.4967 | |
| Total | 2 | 100.0 | 16 | 100 | ||
|
| ||||||
| Yes | 2 | 100.0 | 10 | 62.5 | Exact Fisher | |
| NO | 0 | 0.0 | 6 | 37.5 | p = 0.5294 | |
| Total | 2 | 100.0 | 16 | 100 | ||
| P | ||||||
| Yes | 2 | 100.0 | 9 | 56.3 | Exact Fisher | |
| No | 0 | 0.0 | 7 | 43.8 | p = 0.4967 | |
| Total | 2 | 100.0 | 16 | 100 | ||
|
| ||||||
| 1+ | 0 | 0.0 | 0 | 0.0 | - | |
| 2+ | 2 | 100.0 | 16 | 100.0 | ||
| Total | 2 | 100.0 | 16 | 100 | ||
|
| ||||||
| 1+ | 0 | 0.0 | 0 | 0.0 | - | |
| 2+ | 2 | 100.0 | 16 | 100.0 | ||
| Total | 2 | 100.0 | 16 | 100 | ||
FIGURE 4Epithelioid granuloma, lymphocytes in the perigranuloma area and dermis edema in a patient coinfection with HIV/leprosy. Photomicrography in HE with 40x augmentation